Duloxetine
Product Images NDC 60760-951

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 60760-951). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

951-60 (Duloxetine 951 60)

Label for Duloxetine 30 mg delayed-release capsules USP, quantity 60, NDC 60760-951-60. Manufactured by Rising Health, LLC, Saddle Brook, NJ, and packaged by St. Mary's Medical Park Pharmacy in Oro Valley, AZ. Includes directions to use as directed and storage instructions at controlled room temperature 15°-30°C (59°-86°F).*

FDA Label Image

Figure 1: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (mdd Study 5) (Duloxetine Fig1)

A Kaplan-Meier curve chart displaying the proportion of patients with relapse over time in days post-randomization, comparing placebo and duloxetine treatments. The graph shows two survival curves, one for placebo and one for duloxetine, illustrating the treatment effect on relapse rates.*

FDA Label Image

Figure-2 (Duloxetine Fig2)

A line graph comparing the proportion of patients with relapse over time between two treatments, Duloxetine and placebo. The x-axis represents time from randomization to relapse in days, and the y-axis shows the proportion of patients with relapse. Duloxetine and placebo are depicted with different line styles.*

FDA Label Image

Figure-3 (Duloxetine Fig3)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at doses of 20 mg, 60 mg daily, and 60 mg twice daily compared to placebo. The graph depicts treatment efficacy trends for different dosages of Duloxetine relative to placebo.*

FDA Label Image

Figure 4: Percentage Of Dpnp Adult Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (study Dpnp-2) (Duloxetine Fig4)

A line graph showing percentage of patients improved in relation to percent improvement in pain from baseline. It compares Duloxetine 60 mg BID, Duloxetine 60 mg QD, and Placebo. The y-axis represents percentage of patients improved, and the x-axis shows percent improvement in pain from baseline.*

FDA Label Image

Figure 5 (Duloxetine Fig5)

Line graph comparing the percentage of patients improved against the percent improvement in pain from baseline. It displays three groups: Duloxetine 60 mg Twice Daily, Duloxetine 60 mg Once Daily, and Placebo, showing patient improvement trends across varying levels of pain improvement.*

FDA Label Image

Figure 6 (Duloxetine Fig6)

A line graph depicting percent improvement in pain from baseline on the x-axis against percent of patients improved on the y-axis. It compares four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo. The plot shows a trend of decreasing percentages of patients improved as percent improvement in pain increases.*

FDA Label Image

Figure 7 (Duloxetine Fig7)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for placebo and Duloxetine 60/120 mg once daily. The x-axis shows percent improvement in pain from 0 to 100%, and the y-axis shows percentage of patients improved from 0 to 100%. The graph shows two lines: placebo marked with X and Duloxetine marked with diamonds.*

FDA Label Image

Figure 8 (Duloxetine Fig8)

A line graph comparing the percentage of patients improved between Duloxetine 60 mg once daily and placebo, plotted against percent improvement in pain from baseline (BOCF). The graph shows Duloxetine consistently outperforming placebo across increasing levels of pain improvement.*

FDA Label Image

Figure 10: Percentage Of Adult Patients With Oa Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (study Oa-1) (Duloxetine Fig9)

A line chart comparing the percentage of patients improved in pain from baseline between placebo and Duloxetine 60/120 mg once daily. The x-axis represents percent improvement in pain from baseline (BOCF), and the y-axis shows the percentage of patients improved. Two lines illustrate patient improvement trends for placebo and Duloxetine groups across varying improvement percentages.*

FDA Label Image

Chemical Structure (Duloxetine Str)

Chemical structure of duloxetine hydrochloride showing a naphthalene ring connected to a thiophene ring via an oxygen and a chiral carbon attached to a methylamino group with a hydrochloride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.